(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.74%.
Cervomed's earnings in 2026 is -$26,966,367.On average, 9 Wall Street analysts forecast CRVO's earnings for 2026 to be -$22,932,921, with the lowest CRVO earnings forecast at -$39,379,184, and the highest CRVO earnings forecast at -$5,249,694. On average, 8 Wall Street analysts forecast CRVO's earnings for 2027 to be -$17,077,707, with the lowest CRVO earnings forecast at -$22,139,449, and the highest CRVO earnings forecast at -$3,305,363.
In 2028, CRVO is forecast to generate -$15,535,205 in earnings, with the lowest earnings forecast at -$22,320,920 and the highest earnings forecast at -$3,499,796.